Overview

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Status:
Completed

Trial end date:
2015-07-02

Target enrollment:

Participant gender:

Summary

The primary objective of the study was to compare the safety and efficacy of multiple doses of upadacitinib versus placebo in adults with moderately to severely active rheumatoid arthritis (RA) on stable background methotrexate therapy who had not shown an adequate response to methotrexate alone.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Methotrexate
Upadacitinib